Cwestiynu’r Gweinidog Iechyd ar fynediad i gyffuriau canser.

Elin health

Fy nghwestiynau i’r Gweinidog Iechyd yr wythnos ddiwetha ar drefn newydd i benderfynnu ar fynediad i gyffuriau canser.

Cofnodion islaw, ond dyma linc i’r fideo:
http://senedd.tv/Meeting/Clip/c587b321-b6f1-4b78-b77f-94de0e509ac6?inPoint=0:13:52&outPoint=0:19:09

Elin Jones

Weinidog, mae’r broses o gael mynediad i feddyginiaethau a thriniaethau newydd yn para i fod yn anodd ac anghyson yng Nghymru. Yn yr Alban, fe grëwyd cronfa meddyginiaethau newydd y llynedd ac maen nhw’n bwriadu defnyddio’r arian o’r ‘rebate’ newydd dan y ‘pharmaceutical price regulation scheme’ ar feddyginiaethau newydd. Bydd Llywodraeth Cymru, mae’n debyg, yn derbyn £28 miliwn o’r ‘rebate’ yma eleni. Pam nad ydych chi wedi clustnodi mwyafswm y ‘rebate’ yma—y £28 miliwn—i gael ei ddefnyddio ar gyfer meddyginiaethau newydd yng Nghymru, fel yn yr Alban?

Mark Drakeford

The Member is right to say that we will have £28 million as a result of the rebate and we will apply it in the Welsh NHS in a way that best meets the priorities that we face here in Wales. I have already made an announcement here on the floor of the Assembly that we will be using some of that money, for example, to strengthen the way in which the individual patient funding requests process will run in future and the way in which we will assess orphan and ultra-orphan drugs. But, we will make our own decisions about how we use the money and we will make it in a way that is right for Wales, rather than thinking that we always have to look to copy how someone else has decided to make their decisions.

Elin Jones

Ond rhan fach o’r arian rydych chi’n ei chlustnodi ar gyfer gwella’r gyfundrefn mynediad i feddyginiaethau newydd. Dro ar ôl tro yng Nghymru rydym yn gwybod am bobl sy’n cael eu troi lawr am gyffur newydd oherwydd nad ydynt hefyd yn cwrdd â’r criteria ‘exceptionality’. Mae achos Irfon Williams a’r ymgyrch Hawl i Fyw wedi’n hatgoffa ni unwaith eto o wendid y gyfundrefn sydd gennym ni yng Nghymru. Nawr, mae’r Alban wedi cael gwared â’r criteria ‘exceptionality’. Bythefnos yn ôl, fe gyhoeddodd Gogledd Iwerddon eu bod nhw hefyd yn bwriadu newid y criteria yma’n sylweddol. Er hynny, yng Nghymru rydym yn parhau i ddefnyddio’r criteria annheg ac aneffeithiol yma ar gyfer penderfyniadau sydd mor bwysig.

Mark Drakeford

Well, I don’t accept the basic proposition in the question, Llywydd. The best evidence is that patients in Wales get faster access to drugs that are approved by the National Institute for Health and Care Excellence as being both clinically and financially effective. That’s the evidence and that’s what we use the resources we have here in Wales to support. As Elin Jones knows, we had a full review of our IPFR process here in Wales from an independent and expert group. We’re reforming it as a result to make it more effective, particularly in order to make sure that consistency of decision making across Wales is improved. I think that a system that approves more than half of the applications that are made to it cannot fairly be described—I don’t think that she did describe it in this way, but it is sometimes thought of—as a process designed to deny people the drugs for which they have made an application.

Elin Jones

Weinidog, er yr hyn rydych yn ceisio ei amddiffyn fel newidiadau yn y broses, rydym yn dal i gael cleifion, ac rydym hefyd yn cael clinigwyr, yn dweud wrthym fod y broses yn annheg ac yn anghyson. Dim ond wythnos diwethaf, clywsom ni un Aelod Cynulliad yn adrodd hanes ei hetholwr hi oedd wedi cael ei droi lawr am gyffur gan un bwrdd iechyd yng Nghymru—Aneurin Bevan—ac wedi symud i Gaerdydd ac wedi cael mynediad at gyffur wedyn o dan fwrdd iechyd gwahanol. Fel man lleiaf, Weinidog, wrth edrych ar newidiadau, mae eisiau creu cyfundrefn yng Nghymru sy’n gyson o fewn Cymru, o leiaf, yn hytrach na saith cyfundrefn ar wahân o dan y byrddau iechyd ar wahân. A wnewch chi nawr edrych ar hynny fel man cychwyn i newid y gyfundrefn sydd gennym ni?

Mark Drakeford

Well, on that narrow point, Llywydd, I am very happy to agree with some of the things that Elin Jones has said. It is not acceptable to me that we have decisions being made in identical circumstances but made differently between one health board and another. That isn’t an acceptable position. But changes that are already announced as part of the review will drive better consistency in decision making. But on Monday of this week, I met with the director-general of the NHS in Wales and I have asked him to look again at the recommendations made by the expert group about the number of panels we should have in Wales, and explicitly to give me further advice on whether there are additional ways in which we can try and secure consistency of decision making in this area.

Comments are closed.